Entire population (n = 730) | Cardiac events (n = 123) | No cardiac events (n = 607) | P-value | |
---|---|---|---|---|
Age (years) | 63 ± 12 | 66 ± 10 | 63 ± 12 | 0.002 |
Male sex (%) | 88 | 87 | 88 | 0.349 |
Family history of CAD (%) | 48 | 43 | 49 | 0.063 |
Hypertension (%) | 58 | 59 | 58 | 0.151 |
Diabetes (%) | 27 | 28 | 27 | 0.878 |
Hypercholesterolemia (%) | 59 | 60 | 59 | 0.974 |
No. of stenosed vessels | 1.8 ± 0.9 | ± 0.9 | 1.8 ± 0.9 | 0.09 |
Beta-blocker (%) | 79 | 87 | 77 | 0.06 |
Diuretics (%) | 46 | 69 | 40 | < 0.001 |
ACE-I/ARB (%) | 80 | 84 | 79 | 0.357 |
ANTI ALD (%) | 30 | 46 | 26 | < 0.001 |
> 1 MI (%) | 16 | 25 | 14 | 0.005 |
ICD (%) | 24 | 54 | 18 | < 0.001 |
CMR data | ||||
LVEDV (ml/m2) | 111 ± 41 | 136 ± 46 | 106 ± 38 | < 0.001 |
LVESV(ml/m2) | 71 ± 42 | 99 ± 43 | 65 ± 39 | < 0.001 |
LVEF (%) | 41 ± 16 | 30 ± 10 | 43 ± 16 | < 0.001 |
LV mass index | 77 ± 22 | 82 ± 24 | 76 ± 21 | 0.02 |
LVEF < 30% (%) | 29 | 55 | 24 | < 0.001 |
Dilated LVEDVi | 39 | 67 | 34 | 0.076 |
WMSI | 1.7 ± 0.5 | 2.0 ± 0.5 | 1.7 ± 0.5 | < 0.001 |
WMSI > 1.7 (%) | 52 | 48 | 62 | < 0.001 |
LGE extent (% of LV mass) | 14 ± 8 | 16 ± 8 | 14 ± 8 | 0.003 |
LGE extent > median | 50 | 62 | 47 | 0.003 |
Segments with LGE | 6.0 ± 3.2 | 6.7 ± 3.4 | 5.9 ± 3.2 | 0.02 |
LGE transmural extent 1–50% (no. of segments) | 2.2 ± 2.5 | 2.1 ± 2.4 | 2.2 ± 2.5 | 0.61 |
LGE transmural extent 51–100% (no. of segments) | 3.8 ± 2.9 | 4.6 ± 3.1 | 3.7 ± 2.8 | 0.002 |
CT-F tissue (no. of segments) | 1.9 ± 2 | 1.5 ± 1.7 | 2.0 ± 2.0 | 0.02 |